56. ベーチェット病 [臨床試験数:68,薬物数:87(DrugBank:31),標的遺伝子数:36,標的パスウェイ数:113

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03209219
(ClinicalTrials.gov)
June 30, 20174/7/2017Interferon a2a Versus Cyclosporine for Refractory Behçet's Disease UveitisRandomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet's Disease UveitisBehçet Disease;UveitisDrug: Interferon Alfa-2A;Drug: Cyclosporine PillPeking Union Medical College HospitalNULLRecruiting18 Years65 YearsAll36Phase 3China
2JPRN-UMIN000025451
2017/04/0128/12/2016Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's diseaseClinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease refractory uveitis of Behcet's diseasePatients with Behcet's disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be changed to cyclosporine A oral administration. For cases in which uveitis can not be suppressed and infliximab is reintroduced, if it is 20% or less, it shall be acceptable. Cyclosporine A is started orally at 5 mg / kg / day orally twice a day from 6 weeks after the final Infiximab administration, the maintenance dose is 3 to 5 mg / kg / day, and if the clinical findings are stabilized, Losing weight little by little is judged by the research doctor . The target trough value should be less than 150 ng / ml. The observation period of cyclosporine administration is one year.Yokohama City University HospitalNULLPending20years-old65years-oldMale and Female5Not selectedJapan
3NCT00167583
(ClinicalTrials.gov)
November 20049/9/2005Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)Behcet's Disease;Panuveitis;Posterior Uveitis;Retinal VasculitisDrug: Cyclosporin A;Drug: Interferon-alpha2aUniversity Hospital TuebingenNULLCompleted18 Years75 YearsAll37Phase 3Germany